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Abstract

A potassium loading study was performed in acutely nephrectomized
rats to determine the extrarenal effects of diuretics on potassium
tolerance.

Four diuretics were used - furosemide, hydrochlorothiazide,

spironolactone, and bumetanide.

In all animals studied, there was no

significant difference between animals given diuretics and control
animals in the observed increment in plasma potassium concentration.
Keeping in mind the difficulties inherent in interpreting whole
animal studies, these results suggest that:
1) If the recently postulated furosemide-inhibited cation
cotransport mechanism does exist in the rat, then at the least this
transport mechanism is not the dominant mechanism for determining
potassium balance in the whole animal model.
2) There is no thiazide-induced extrarenal impairment or
improvement of potassium tolerance.
3) Blockade of aldosterone with spironolactone does not cause
impaired extrarenal potassium disposal as has been recently suggested.
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Introduction

Diuretics are among the most commonly used pharmacologic agents
in clinical medicine.

They are classified according to chemical

structure and by their major sites of action in the kidney.

Yet,

with the exception of the carbonic anhydrase inhibitors, relatively
little is known about their mechanisms of action.

That this should

be so goes hand in hand with the fact that the intimate details of
the structure and biochemical functions of the renal epithelium
remain obscure.

Elucidation of the mechanisms of action of the

various classes of diuretics would doubtless provide invaluable
insight into the mechanisms of ion transport in the tubular cell of
the kidney, and in a broader sense to our understanding of renal
physiology as wel1.
It appears that the actions of many diuretics are not limited
to the renal epithelium.

For example, furosemide has been shown to

cause a prompt increase in venous capacitance which precedes its
diuretic effect (1).

This has been useful in the treatment of

pulmonary congestion and pulmonary edema in the setting of elevated
left ventricular filling pressure associated with acute myocardial
infarction (1).

Furosemide has also been used as an antihypertensive,

as have diuretics of other chemical groups including thiazides and
aldosterone inhibitors.

Their effect of lowering blood pressure has

been demonstrated to persist even after their diuretic effect has
ceased (2-4).
Much of the work in this laboratory has been devoted to the study
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of the regulation of potassium balance by the kidney and by extrarenal
mechanisms.

In view of the ubiquitous use of diuretics in clinical

medicine, and in view of data suggesting that they have extrarenal
effects not only on hemodynamic regulation as mentioned above but on
regulation of ion transport as well, it seemed of interest to pursue
study of the effects of these drugs on extrarenal potassium disposal.
The background for this work is discussed in detail in later sections
and briefly below.

1. Furosemide in large doses is often used to treat patients with
acute renal failure in an effort to convert an oliguric state to a
non-oliguric one.

When successful, this effect is thought to involve

changes in renal vasuclar resistance and renal blood flow (5-9).

More

recently, furosemide has been used in defining an ion cotransport
mechanism which exists in several cell systems, including avian (10-13)
and human red blood cells (14-18) and the loop of Henle (19 20).
system, which transports Na, K, and Cl
by furosemide.

This

intracel1ularly, is inhibited

The ability of furosemide and other aminobenzoic acid

derivatives such as bumetanide to act as inhibitors of the transport
system is directly correlated with their diuretic potency (10), leading
to speculation as to the significance of this mechanism within the
renal epithelium.

Moreover, if this cotransport system has major

significance in the whole animal, then its effects on ionic, specifically
potassium, balance must be considered.

In the setting of acute renal

failure, if use of furosemide could result in decreased potassium
tolerance due to inhibition of cotransport, then there is a potential
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for development of life-threatening hyperkalemia.

2. Thiazides are known to lower plasma potassium in certain
disease states where hyperkalemia is found in the presence of normal
renal function (21-24).

Recently there has been a case report

involving hyperkalemia associated with hypertension in which both
abnormalities were corrected with thiazide administration (24).
Interestingly, however, urinary K excretion did not significantly
increase with the diuretic, implying that correction of the
hyperkalemia was not due to increased potassium losses.

In short,

an extrarenal effect of thiazides on potassium disposal is suggested.

3. Aldosterone has recently been shown to have an extrarenal
effect on potassium disposal

(25).

The effect of mineralocorticoids

on extrarenal potassium homeostasis is discussed in detail in the
following section.

Briefly, mineralocorticoids appear to enhance

K uptake by extrarenal tissues (26-28), and extrarenal K tolerance
is diminished in their absence (29,30).

By extrapolation, one would

expect then that mineralocorticoid inhibition, for example with such
agents as the aldosterone antagonist spironolactone, might have an
opposite effect on extrarenal K balance..

There has been little work done on the role of diuretics on ion
transport outside the kidney.

We therefore undertook this study to

examine the effects of diuretics of three chemical families on
extrarenal potassium disposal.

The diuretics used were furosemide.

5

bumetanide, hydrochlorothiazide, and spironolactone (Figure 1).

As

an understanding of extrarenal potassium regulation is essential to
this project, a brief overview of factors currently believed to be
involved in this regulation follows.
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Background

A wealth of literature has been devoted to the discussion of the
regulation of extracellular potassium concentration.

Extracellular

potassium represents only 2°l of total body potassium, or approximately
65 mEq in a 70 kg man.

Elucidation of the complex mechanisms by which

this relatively small pool of potassium is controlled has proved to
be a fascinating albeit extremely difficult task.

While our understanding

of the cellular mechanisms of potassium homeostasis has greatly
expanded in recent years, it is still limited, and much of the regulation
of cellular potassium transport as well as the broader area of cellular
ion transport remains to be fully evaluated.
The kidney is a major regulator of potassium homeostasis; renal
mechanisms are important determinants of extracel1ular potassium
balance in chronic disease or health.

However, it has become increasingly

clear that extrarenal mechanisms play an important role in overall
potassium homeostasis, particularly in settings of acute potassium
imbalance (25).

With the use of newer techniques and with increasing

utilization of cellular probes in the form of drugs and hormones, our
understanding of extrarenal potassium regulation has broadened.
Moreover, a greater appreciation of the mechanisms of extrarenal
cellular potassium transport and regulation can be applied to further
our understanding of renal mechanisms of K transport, and to our
understanding of the physiology of the kidney.
There are a number of extrarenal factors which interact to a
greater or lesser degree with chronic as well as acute K homeostasis.

7

The details of these interactions have obviously not been fully worked
out; however, it has become clear that renal potassium excretion may
well not be the most important factor in the handling of an acute
K load (25).

It has been shown in humans (31-33), in dogs (31), and

in rats (34) that less than 50% of an acute exogenous K load is
excreted by the kidney in the first four to six hours following
administration (25).

The greater part of the remainder of the K load

is transported into the intracellular compartment by extrarenal mechanisms,
thus defending the extracellular fluid from life-threatening hyperkalemia.
These mechanisms have been reviewed extensively in a recent review by
Bia and DeFronzo (25), and will be discussed only briefly here.

Acid-Base
It has long been appreciated that acid-base balance can affect the
distribution of potassium.

Fenn and Cobb in 1934 showed that lowering

the pH of a skeletal muscle preparation caused movement of K out of
muscle cells into the surrounding medium (35) and suggested that there
was a connection between intra- and extracellular hydrogen ion and
potassium ion concentrations.

Since then it has been the general

conclusion that intra- and extracel1ular acid-base balance and potassium
status are integrally and reciprocally related (36).

Acidosis causes

the plasma K concentration to increase due to displacement of K
extracel1ularly in exchange for the buffering of excess H ions
intracellularly, with the opposite exchange occuring during alkalosis.
Burnell et al. quantitated the increments in K and pH in five patients
with various types of acid-base disturbances and calculated that, on
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the average, for every 0.1 unit change in extracellular pH there was
an inverse change of 0.6 mEq/L in the serum K concentration (37).
This numerical relationship is commonly used as a guideline to estimate
a corrected K concentration in the presence of an acid-base disturbance.
However, it has been pointed out in recent years that the relationship
between hydrogen ion and potassium concentrations is far more complex
than has been assumed (25,36), and that the variation of plasma K
increments observed with an 0.1 unit pH change is considerable (25).
As noted by Bia and DeFronzo (25) and by Adler and Fraley (38), a
number of factors, including the nature of the disturbance (i.e.
metabolic vs. respiratory), the type of anion accompanying an increase
in hydrogen ion concentration, the duration of acidosis, and the extent
of intracellular buffering, as well as the type of imbalance itself
(i.e. acidosis vs. alkalosis) affect the relationship between the
two ions.

Moreover there is evidence that the plasma bicarbonate

concentration also may alter potassium distribution, independent of
the blood pH (38,39).

Although the original observation of the

reciprocal relationship between hydrogen ion and potassium concentration
has been confirmed repeatedly, the complexity of the relationship has
been underestimated, and the exact nature of the interactions between
acid-base balance and potassium regulation remains to be defined.

Hormones
I. Insulin
Much effort has been concentrated recently on determining the
effects of various hormones on extrarenal K regulation.

Of the major
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hormones known to affect potassium homeostasis, insulin is probably
the best described.

Harrop and Benedict (40) and Briggs et al.

(41)

in 1923 noted that insulin administered to the intact animal produced
a decrease in serum potassium concentration.

This observation has

subsequently been demonstrated and further described by a number of
investigators (32, 42-47) and it is now well established that insulin
plays an important role in the disposal of an acute potassium load.
It has been shown by several groups that infusion of KC1 resulting in
an elevation of plasma K to a significant degree of hyperkalemia
(i.e. an increase of greater than 1.0-1.5 mEq/L (25)) causes an
increase in peripheral insulin levels and a stimulation of pancreatic
insulin secretion (45,46).

The relative clinical importance of this

relationship may be evident in the setting of acute hyperkalemia due
to hemolysis, rhabdomyolysis, severe crush injuries, and burns, etc.
Perhaps more importantly, however, it has recently been demonstrated
that basal insulin levels play a role in potassium homeostasis (43).
DeFronzo et al. (43) have shown that in dogs given a relatively small
KC1 infusion (0.375 mEq/kg/hr), serum K increased by only 0.5-0.7 mEq/L,
remaining within the normal physiologic range, and under these conditions
basal insulin levels remained unchanged.

However, when somatostatin,

a potent inhibitor of insulin and glucagon secretion, was infused with
KC1, serum K levels doubled over control values.

Moreover, suppression

of basal insulin secretion in normal dogs, normal human subjects, and
maturity-onset diabetics by somatostatin in the absence of KC1 infusion
was associated with a significant rise of baseline plasma K concentrations.
This effect was independent of and preceded any changes in plasma glucose
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and was also noted to be present in the absence of any change in renal
K excretion, implying that the effect of basal insulin secretion on
plasma K concentration was extra-renal in nature.

That this was an

effect of lack of insulin rather than glucagon was supported by the fact
that in juvenile-onset diabetics lacking endogenous insulin secretion,
no change in plasma K concentration was seen after infusion of
somatostatin.

A permissive role for basal insulin levels on K regulation

is thus suggested.

It should be noted, however, that peripheral

measurements of insulin levels may not accurately reflect the secretion
of insulin by the pancreas.

Blackard and Nelson (48) have demonstrated

that portal and peripheral vein insulin concentrations differ by a
ratio of approximately 2-3:1.

It has been shown that extremely small

increments of plasma insulin (e.g. 25^cU/ml) can cause stimulation
of K uptake by various tissues (49).

Hence the postulated permissive

role of basal insulin secretion on tissue K uptake must be modified
to include the possibility that portal insulin levels may be
sufficiently elevated to actively augment hepatic K uptake in the absence
of any measurable increase in peripheral insulin levels (25).

In this

instance, use of a C-peptide assay as an analytic tool for measuring
pancreatic insulin secretion might be a reasonable alternative.
In the absence of insulin the ability to tolerate an acute potassium
load is markedly impaired.

This has been demonstrated in pancreatectomized

dogs (44,45,50) as well as in dogs, rats, and humans infused with
somatostatin (34,43,46,47,51,52) and is independent of any change in
renal K excretion.

The ability to dispose of a potassium load

intracel1ularly is restored when insulin is replaced.

The clinical
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importance of this mechanism is evident in such obvious ways as the
use of insulin (along with glucose) in the treatment of life-threatening
hyperkalemia.

It is tempting to speculate that in the clinical setting

of insulin lack, that is in the setting of diabetes, the not infrequent
occurrence of hyperkalemia may be due at least in part to the
insulinopenia itself as well as to the increase observed in plasma
tonicity and, as recently postulated, in some cases also to concomitant
hypoaldosteronism (26).
It has been shown by several groups that insulin-enhanced cellular
K uptake involves muscle (53-57) and liver (58-60), which serve as the
major body potassium storage pools.

That the stimulation of cellular

K uptake is distinct from the action of insulin on cellular glucose
uptake is supported by the observations that a) the temporal courses
of potassium and glucose movement differ (61), b) the potassium uptake
can be shown to occur unchanged in glucose-free medium (55,56), and
c) potassium uptake can be stimulated maximally by insulin concentrations
too small to effect glucose transport (62).
The cellular mechanism by which K uptake is stimulated by insulin is
thought to involve hyperpolarization of the cell membrane.
al.

Zierler et

(55-57) in a system using rat skeletal muscle have shown that the

movement of potassium is not sufficiently large enough nor does it occur
rapidly enough to explain the insulin-induced increase in the transmembrane
potential difference, and have surmised that the movement of potassium
occurs as the result of the hyperpolarization rather than as its cause.
They have suggested that perhaps K movement is enhanced due to some
alteration of the permeability of the cell membrane secondary to the
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hyperpolarization which allows the ion (and perhaps other substrates
such as glucose) to move passively intracellularly (55,57).

II. Catecholamines
That catecholamines are involved in the regulation of potassium
homeostasis was first noted by D'Silva, who in the 1930s demonstrated
that injection of epinephrine into normal cats caused a transient
increase in plasma potassium which was followed by a sustained
decrease in plasma potassium (63,64).

This initial hyperkalemic

effect was presumed to be the result of increased hepatic potassium
release, as supported by the observation that there was an increase
in hepatic venous potassium concentration after epinephrine injection.
The effect of sustained hypokalemia that followed was felt to be
secondary to increased tissue uptake of potassium.

Since then,

catecholamines have been shown to play a significant role in the
regulation of potassium in both the kidney and in extrarenal tissues
(25,34,65-68).
DeFronzo et al. (68) recently demonstrated that infusion of KC1
with epinephrine into normal humans leads to a marked inhibition of
the increased renal K excretion that is observed with KC1 infusion
alone.

Yet the rise in plasma K was less in subjects who had received

both KC1 and epinephrine as compared to subjects who received KC1
alone, indicating that potassium tolerance is improved in the presence of
catecholamines, presumably due to enhanced cellular uptake.

Increased

cellular uptake of K in response to catecholamine has been demonstrated
clearly in skeletal muscle, the major potassium storage tissue (69-72),
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and some investigators have also reported an increased uptake in liver
(69-71).

That this effect is distinct from the action of insulin has

been demonstrated by Petit and Vick (73) in studies of pancreatectomized
dogs.

Response to epinephrine in experimental animals did not differ

significantly from pancreatectomi zed controls, indicating that the
enhanced cellular uptake of K did not depend on the release of insulin (73).
Moreover, hyperglycemia per se was also found not to affect the response
to epinephrine (74).
The mechanisms by which catecholamines bring about their biphasic
effects on plasma K concentration have been worked out to some extent.
Lockwood and Lum (69,75) and Todd and Vick (76) used adrenergic agonists
and antagonists to show that the early hyperkalemic effect of
catecholamines depends on both ©<- and ^-adrenergic properties, while
the secondary hypokalemic effect resulting from enhanced cellular
uptake is apparently a purely ^-adrenergic function.

These authors

have shown that p,-agonist activity is protective against a KCl-induced
hyperkalemia, and that this protective effect can be abolished by the
^-blocking agent propranolol.

Further work with more selective ^ and

agents have shown that the stimulation of cellular K uptake is most
likely due to specific ^,-agonist activity (e.g. by the selective ^>agonists salbutamol and soterenol) and can be prevented by selective
^-antagonists (e.g. Butoxamine).

Of clinical interest in this regard

is the report by Wang and Clausen of the successful treatment of attacks
in hyperkalemic familial periodic paralysis by salbutamol inhalation,
presumably due to stimulation of cellular potassium uptake (77).
Recently, reports of impaired K tolerance following

^-blockade in
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man have prompted the study of the effects of ^-blockade itself on
potassium balance (67,68).

As described above, infusion of KC1 with

epinephrine into normal subjects causes an inhibition of the increased
renal K excretion observed with KC1 infusion alone (68), yet plasma K
rises less in those subjects given KC1 and epinephrine than in those
given KC 1 alone,

^-blockade in the form of propranolol abolishes

this effect of epinephrine.

Interestingly, however, when propranolol

is given with KC1 infusion and no epinephrine is given, a greater
increase in plasma K is noted than when KC1 is given alone, suggesting
that basal epinephrine levels may play a role in K regulation, as is
thought to be the case with basal insulin levels (67,68).
Although the pharmacology of the catecholamine effect on cellular
K uptake has become more clear in recent years, the mechanisms by which
the epinephrine-stimulated K transport occurs have yet to be worked out.
Moreover, the effect of potassium itself on regulation of catecholamine
production is not known.

It has been suggested that potassium may act

as a stimulus to catecholamine release by the adrenals (78,79).

Vogt

demonstrated that injection of KC1 into the celiac artery causes increased
release of sympathomimetic amines into the adrenal vein (79), and
Silberstein et al. have demonstrated that incubation of adrenal glands
in media with elevated potassium concentrations results in increased
activity of tyrosine hydroxylase (the first enzyme in the biosynthetic
pathway of catecholamines) and in an increase in the amount of epinephrine
released from the gland (78).

However, Vogt failed to report the dose of

KC1 infusion used in her system, and the 50 mM K concentration of the
medium used by Silberstein et al. seems hardly physiologic.

The complex
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interrelationships between potassium regulation and catecholamine
synthesis, function, and effect are obviously still far from being
fully understood.

III. Mineralocorticoids
The effect of mineralocorticoids in augmenting potassium secretion
by the kidney has been described (80-83).

This kaliuretic effect

is observed in response to acute mineralocorticoid exposure as well
as with prolonged treatment in contrast to the sodium "escape" phenomenon
that occurs in the kidney with prolonged mineralocorticoid exposure (80).
The action of these agents in the kidney has been localized to sites in
the distal tubule and collecting system (84).
Hyperkalemia is known to act as a stimulus to aldosterone secretion
(85,86).

It has been suggested that in the absence of an intact renin-

angiotensin system changes in potassium concentration may be the major
regulator of aldosterone production (87).

Laragh and Stoerk demonstrated

that increased K intake resulted in aldosterone hypersecretion (88).
Subsequently, Blair-West et al. demonstrated that KC1 infusion leading
to increased plasma K concentration within the normal physiologic range
had an aldosterone-stimulating effect resulting in a significant elevation
in adrenal vein aldosterone levels, and postulated that the effect
observed earlier by Laragh and Stoerk had been due to a direct action of
the increase in plasma K on the adrenal gland (89).

Since then the

biochemical synthetic pathway for aldosterone in the zona glomerulosa
of the adrenal has been worked out, and the fact that potassium stimulates
both an early and a late step in aldosterone synthesis (notably the
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conversions of cholesterol to deoxycorticosterone and corticosterone
to aldosterone (90)) is consistent with their earlier observations (26).
That an increase in plasma K causes increased aldosterone secretion
makes teleologic sense since a major physiologic effect of aldosterone
is to increase K excretion via the kidney.

However, aldosterone is

thought to have significant effects on potassium regulation by
extrarenal tissues as well.
Aldosterone is known to cause a decrease in the Na/K ratio in
secretions of salivary glands, sweat glands, and colon (91-94).
However, there have been conflicting views as to the effect of
mineralocorticoids on K transport in other extrarenal tissues known to
contain large amounts of exchangeable intracellular potassium, notably
muscle and liver.

Several groups have reported a decrease in potassium

content of muscle after exposure to aldosterone (95,96); in contrast
other groups have shown no change in muscle potassium content (27,28).
Moreover it has been suggested that increased uptake of K occurs but
that perhaps the potassium increment in any one tissue is too small to
be measured (28,97,98).

Bia and DeFronzo (25) have pointed out that

these differences may have risen from a number of discrepancies among
studies:

species differences, failure to examine overall K balance,

acid-base status, systemic hemodynamics, differences in aldosterone
and potassium doses, and differences in the levels of other potassiumregulatory hormones.

These authors, however, feel that mineralocorticoids

do cause an enhancement of K uptake by extrarenal tissues (25).

In vivo

studies in normal rabbits infused with aldosterone (27) and in
adrenalectomized rats treated with deoxycorticosterone acetate (28) have

I
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shown that mineralocortioid administration decreases plasma K and that
this decrease cannot be explained by increased renal or fecal K losses.
In a similar vein, in adrenalectomized dogs an increase in plasma K
was observed which could not be explained by decreased K losses in
urine or stool (29).

Moreover, in nephrectomized rats, hyperkalemia

resulting from KC1 loading was significantly greater in adrenalectomized
animals versus controls (30).

Furthermore, in the syndrome of

hyporeninemic hypoaldosteronism in man in which hyperkalemia is often
the presenting complaint, it has been noted that replacement of
mineralocorticoid results in correction of the elevated plasma K without
a concomitant increase in urinary K excretion (26).
Hence it appears that in the whole animal mineralocorticoid
enhances extrarenal potassium disposal

(25), and likely plays an

important role in overall extrarenal potassium homeostasis.

This is

probably the result of mineralocorticoid-induced increased cellular
uptake of K by extrarenal tissues; however, it has been difficult to
document this in isolated tissue systems, and the mechanisms by which
this uptake occurs remains obscure.

IV. Gluoocorticoids
Glucocorticoids have been shown to produce a transient increase in
renal potassium excretion which is distinct from the kaliuresis induced
by mineralocorticoids (25).

Some investigators have also reported a

transient increase in plasma K with acute glucocorticoid administration
(99,100),, suggesting that there is an extrarenal effect of these
hormones on K homeostasis.

Studies done in hyperkalemic adrenalectomi$d
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dogs in which chronic cortisone administration corrected the plasma K
imbalance in the absence of a significant increase in renal K excretion
support this postulate (101).

Also, recent work done in human red

blood cells has demonstrated that exposure to glucocorticoids causes an
increase in ouabain sites (102).

This respresents an increase in the

number of Na-K ATPase pump sites, which may be the cellular mechanism
responsible for the seemingly increased capacity to pump K
intracel lularly (102).
The effects of glucocorticoids on extrarenal tissues has been
relatively unexplored with the exception of the gastrointestinal tract.
Glucocorticoids are known to affect electrolyte transport across the
intestinal epithelium, resulting in an increase in the transepithelia 1
potential difference (103-105).

In adrenalectomized rats, secretion of

K and reabsorption of Na by colonic epithelial cells decreases, and there
is a reduction in the transepithelial potential difference (105).
Physiologic doses of dexamethasone replacement restore electrolyte
transport and the potential difference to normal levels (105).
et al.

Charney

(103) demonstrated that there is an association between intestinal

electrolyte transport and the activity of mucosal Na-K ATPase activity.
Administration of mineralocorticoid caused an increase in K secretion and
a decrease in Na reabsorption in the intestinal epithelium, and this was
felt to be related to the concomitantly increased ATPase activity.
However, Binder more recently has shown a temporal distinction between
the increase in membrane potential difference resulting from electrolyte
transfer and the increase in the Na-K ATPase activity and has suggested
that the increase in K transport seen with administration of dexamethasone
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is not the result of increased enzyme activity as Charney et al. had
postulated.

It should be noted, however, that it is clear that the

rate of K secretion is linked to the activity of the Na-K ATPase in
the colonic epithelium, as has been recently confirmed by Hayslett et al.
(106), albeit the glucocorticoid-induced increased K secretion may not
operate via this mechanism.
V. Glucagon
In light of the major effects of insulin on extrarenal K balance,
it would seem to follow that its endocrine pancreatic counterpart
glucagon should also play a role in K homeostasis.

A transient hyper-

kalemic effect of glucagon infusion distinct from its glycogenolytic
action has indeed been identified (107,108).

However, these studies

were performed using pharmacologic doses of glucagon, and the effect
of smaller, more physiologic amounts of the hormone on K balance
remains to be established.
Cotransport
The cation cotransport system is a relative newcomer to the array
of possible regulators of potassium homeostasis.

A number of transport

systems are known to operate within cell membranes to regulate intraand extracellular concentrations of ions and organic compounds.

In the

particular case of potassium, two systems of K movement have been
described:

1) the well-defined, ATPase-driven, ouabain-sensitive Na-K

pump which causes Na efflux and K influx at the expense of energy in the
form of ATP, and 2) passive K efflux which allows potassium to "leak" out
of cells down its concentration gradient.

Recently there has been
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described a third form of ion cotransport which has been recognized in
a variety of tissues including avian erythrocytes (10-13), mouse fibro¬
blasts (114), human erythrocytes (14-18), Ehrlich ascites tumor cells
(111.115) , as well as the loop of Henle (19,20),

While there has been

a great deal of speculation about the exact nature of the system, it
now appears that this cotransport mechanism is capable of producing
net Na and K movement into cells and is dependent on the presence of
extracellular chloride (15,110,111,113).

Geek et al. in a model using

Ehrlich ascites tumor cells have shown that the net flux of all three
ions occurs inwardly, with an apparent stoichiometry of 1 K+: 1 Na+:
2 Cl" (19, 114).
That this cotransport mechanism is distinct from the better known
Na-K ATPase pump is made clear by the fact that it is ouabain-insensitive
(10,11,14-T7,114,115).

In the presence of ouabain, the Na efflux and

K influx of the Na-K ATPase pump ceases, but the cotransport flux
continues.

However, the cotransport mechanism is subject to hormonal

and pharmacologic manipulations, and may also be sensitive to cellular
volume (12,113,114,116,117), and is inhibited by propranolol (12) and by
diuretic agents of the aminobenzoic acid family including furosemide
(10.14.18.20.114.115) and bumetanide (10).
Energy for the cotransport process is probably derived from the
Na (and perhaps also Cl) electrochemical potential difference (14,109).
By coupling potassium to the process of Na movement, it can be effectively
transported against its own concentration gradient.

This mechanism would

therefore fall under the category of secondary active transport.

As

recently reviewed by Aronson (119), secondary active transport mechanisms
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cause the transport of one substnace against its concentration gradient
by coupling its movement to the movement of another substance down a
favorable gradient, and does not involve direct linkage to a metabolic
process.

Such mechanisms have been described in a variety of tissues

in which the transport of amino acids, sugars, and ions are coupled
to Na movement (109).

This is as opposed to primary active transport in

which transport is directly linked to a metabolic process.

The Na-glucose

cotransport that occurs in the proximal tubule is a well-described
example of the former; the Na-K ATPase pump ubiquitous in cells is an
example of the latter.

Hence with secondary active transport electro¬

chemical ly unfavorable events can by effected by coupling to electrochemically favorable ones without the direct expenditure of metabolic
energy.

In the cotransport mechanism described above, K transport would

be coupled to the flow of Na down its electrochemical gradient.

In this

case Cl also moves down its concentration gradient, and probably
contributes to the transport of potassium.
While the entity of this particular cotransport model seems well
established, its physiologic function remains to be explained.

Several

authors have proposed that it operates in opposition to the Na-K ATPase
as a regulator of cellular volume (11,12,113,114).
a mechanism for transporting K into cells.

It may also serve as

Of particular interest to

this study is the fact that drugs with diuretic properties are known to
inhibit the cotransport system (10,14,18,20,114,115,119).

Moreover,

Palfrey et al. (10) have shown that within this class of agents, diuretic
potency is directly related to inhibitory ability.

That natriuretic

effect should be directly correlated to the ability to specifically
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inhibit the cotranport mechanism is a provocative finding, and it is
tempting to speculate that this is the mechanism for "active" chloride
reabsorption in the thick ascending loop of Henle as has been
suggested (19,20).

That this would have far-reaching implications in

the understanding of the physiology of the renal epithelium is evident.
However, this remains speculation, and the true physiologic importance
of the cotransport system i_n vivo in the whole animal remains to be
elucidated.
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Materials and Methods

In order to evaluate the extrarenal effects of diuretics on
potassium tolerance in acutely nephrectomized rats, a potassium
loading study was performed in male Sprague Dawley rats (Charles River,
Boston, MA).

All rats weighed between 225-265 grams and were divided

into the following four groups:
Group la - Furosemide group
Six rats received an acute intravenous dose of furosemide
(20 mg/kg) 30 minutes prior to the infusion of KC1 (Figure 2
In a separate study this dose of furosemide was shown to
induce a diuresis in rats.
Ib - Furosemide control group
Six rats received an intravenous dose of D^W equivalent in
volume to an appropriate furosemide dose 30 minutes prior
to the infusion of KC1.
Group 11a - Hydrochlorothiazide (HCTZ) group
Six rats receive an acute intravenous dose of HCTZ
(5 mg/kg) 30 minutes prior to the infusion of KC1 (Figure 2)
The HCTZ was dissolved in 32% ethanol in D^W.

This dose of

HCTZ was shown to induce a diuresis in rats in a separate
study.
IIb'- Hydrochlorothiazide control group
Six rats received an intravenous dose of 32% ethanol in D^W
equivalent in volume to an appropriate HCTZ dose 30 minutes
prior to the infusion of KC1
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Group Ilia - Spironolactone group
Six rats received spironolactone (10 mg/kg) subcutaneously
24-30 hours prior to study.

This dose was repeated 210

minutes prior to KC1 infusion (Figure 2). The spironolactone
was dissolved in DMSO.
111b - Spironolactone control group
Six rats received a dose of DMSO equivalent in volume to
an appropriate spironolactone dose 24-30 hours prior to
study, and again 210 minutes prior to KC1 infusion.
Group IVa - Bumetanide group
Three rats received bumetanide (0.25 mg/kg) intravenously
30 minutes prior to KC1 infusion (Figure 2). The bumetanide
was dissolved in 10% ethanol in D^W.
IVb - Bumetanide control group
Three rats received an intravenous dose of 10% ethanol in
DgW equivalent in volume to an appropriate dose of
bumetanide 30 minutes prior to KC1 infusion.
During each K loading study, a diuretic treated rat was studied with a
concomitant control in order to control for time-related changes in
each parameter examined.
All animals were maintained on 15 grams of Standard Purina Rat
Chow (Na and K content equal to 2.5 and 4.0 mEq/day, respectively) for
4-7 days before study.
each day.

All rats consumed the entire 15 grams of chow

All rats were allowed free access to water.
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Potassium loading study
Rats were fasted from the evening prior to study.

In the case of

animals in Group Ilia (spironolactone) and 111b (DMSO), a dose of the
appropriate drug was administered subcutaneously 24-30 hours prior to
study and again at approximately 210 minutes before KC1 infusion of the
day of study.

On the day of study, the animals were anesthetized with

Inactin (Promonta, Hamburg, Germany), 12 mg/ 100 gm body weight
intraperitoneally.
anesthesia.

Surgery was begun approximately 15 minutes after

Body temperature was maintained between 37-38° by means of

a warming board and an overhead desk lamp; temperature was monitored by
rectal thermometer.
A midline skin incision was made in the neck and a tracheostomy
tube inserted to ensure adequate ventilation.

The right external jugular

vein and the left carotid artery were then cannulated with PE-50 tubing.
All test substances were infused through the venous catheter and all
blood samples were withdrawn through the arterial catheter.

Blood

pressure was measured via the carotid catheter.
Following neck surgery a midline abdominal incision was made and
bilateral nephrectomy performed.
was left intact.

The blood supply to the adrenal glands

All animals received a 1% body weight bolus of 0.15 M

NaCl over 20 minutes following neck surgery, and a maintenance infusion
of 0.15 M NaCl at 0.35 ml/ 100 gm body weight/ hour thereafter.

A

Harvard pump (Harvard Apparatus, Mill is, MA) was used to deliver all
infusions.

The abdominal incision was closed with surgical staples.

Following an equilibration period of approximately 60 minutes
(T = -60 to T = 0, see Figure 2), two carotid blood samples (E-j and
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E^) were obtained 15 minutes apart (T = 0 and 15) for analysis of
equilibration period plasma Na and K concentrations.

Immediately

following the second blood sample, an intravenous dose of the
appropriate diuretic or its control substance was given in Groups
la and lb, 11a and 11b, and IVa and IVb, temporarily interrupting the
maintenance NaCl infusion for approximately one minute.

The volume

of the dose of drugs and controls varied between 0.40 and 0.50 ml.
No drug was given at this time in Group Ilia and 111b.

Two more

carotid blood samples (B-j and B^) were obtained 15 minutes apart
(T = 30 and 45) for analysis of baseline plasma Na and K concentrations.
At T = 45 minutes, the saline infusion was replaced with an infusion
of 0.5 M KC1 administered at 0.35 ml/ 100 gm body weight/ hr to deliver
0.17 + 0.02 mEq of potassium per 100 gm body weight per the hour period
of KC1 infusion.

Four carotid blood samples (T-j , Tg, T^, and T^'at1

T = 75, 90, 105, and 120 minutes) were obtained.
All samples were collected in Red-Tip Heparinized Micro-Hematocrit
capillary tubes (Fisher Scientific Co., Pittsburg, PA).

The patency

of the carotid catheter was maintained with heparinized saline (30

/ml).

Approximately 0.20 ml of heparinized saline was given to each animal
via the carotid catheter after each blood sampling to replace the vdliume
of blood loss.

Hematocrit was measured on every blood sample.

pressure was measured at T = 15, 45, 75, and 105 minutes.

Blood

Blood

pressure measurements were made with a U-tube mercury manometer connected
by rigid tubing to the carotid artery catheter.

The manometer was

calibrated daily to correct for changes in barometric pressure.
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In a separate study, the diuretic effectiveness of the doses
used for Groups la and lb and Ila and 11b were evaluated (Figure 3).
Experimental animals underwent neck surgery as outlined above,
but nephrectomy was not performed.

Instead, a lower midline

abdominal incision was made and a catheter inserted into the bladder,
taking care not to disturb the ureters.

Following an equilibration of

approximately 60 minutes, two carotid blood samples (P-j and P2) were
obtained 30 minutes apart (T = 15 and 45 minutes) for analysis of
baseline Na and K concentrations.
intervals.

Urine was collected over 30 minute

Two baseline urine collections (U-j and U^) were obtained

at T = 30 and 60 minutes (see Figure 3) and were analyzed for Na and
K concentrations and volume.

At T = 60 minutes, a chosen dose of

diuretic or an equivalent volume of its respective control was
given intravenously over approximately one minute.

Four more carotid

blood samples (PE-j , PE^, PE^, and PE^ at T = 75, 1 05, 135, and 165
minutes) and four more urine collections (UE-j , UE^, UE^, and UE^ at
T = 90, 120, 150, and 180 minutes) were taken for analysis as
outlined above.

An effective diuretic dose was a dose that resulted

in both an increase in urine volume and an increased natriuresis.
The dose of spironolactone used (10 mg/kg) was arbitrarily
chosen as approximately five to ten times the average effective oral
mg/kg dose in man.

Administration of spironolactone to test animals

was via a subcutaneous route.

Each animal was given two doses of the

diuretic, the first 24030 hours prior to study and the second
approximately 210 minutes prior to KC1 infusion.
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Bumetanide, like furosemide, is a 3-aminobenzoic acid derivative,
but bumetanide has a higher milligram potency.
furosemide at l/40th the molar dose (119).
ineffective as a diuretic in the rat (120).

It is equipotent with

However, bumetanide is
The dose of bumetanide

used (0.25 mg/kg) was arbitrarily chosen as approximately 2.5 times
the intravenous dose known to produce a diuresis in dogs (121).

Analytic methods
Hematocrits were measured by collecting blood samples in
heparinized capillary tubes which were spun for three minutes on a
Micro Hematocrit IEC MB Centrifuge (Demon/IEC Division, Needham Heights,
MA), and subsequently read on a Micro Hematocrit Reader.
Plasma and urine Na and K concentrations were measured with a
flame photometer (Instrumental Laboratories, Watertown, MA) using an
internal lithium standard.

Blood pH and plasma bicarbonate levels

were not obtained.

Calculations
In Groups la, lb, 11a, 11b, IVa, and IVb, mean baseline plasma
Na and K concentrations were obtained by averaging two measurements
obtained 15 minutes apart (B-j and B£) during the 30 minutes after
animals had received their respective drugs or control substances,
but before KC1 infusion.

In Groups Ilia and 111b, mean baseline plasma

Na and K concentrations were obtained in identical fashion in the 30
minutes prior to KC1 infusion; in this case the drug and its control had
been given at 24-30 hours prior to study and again at 210 minutes prior to
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KC1 infusion.

In all groups, plasma Na and K increments above

the baseline mean at T = 75, 90, 105, and 120 minutes were calculated
for each animal.

The rise in plasma K concentration at the end of

each timed interval was used as an index of K tolerance.

Changes in

plasma Na and K concentrations at these times as well as changes in
hematocrit and blood pressure were calculated for all animals.

Results

of each group were then compared to its respective control group and
analyzed by the Student t-test.

Results are listed in Tables 1 and 2.

All values are given as the mean + the standard error of the mean.
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Results

Weights
Mean body weight in each group a was not significantly different
from its respective control group b.

Mean weights at the time of

study were:
Group la
I la

241.3+4.1 grams

lb

242.2 +4.3 grams

234.3 + 7.6 grams

IIb

233.7 + 6.7 grams

Ilia 247.0+4.1 grams

Illb 246.8 + 3.7 grams

IVa

IVb

235.0 + 4.7 grams

236.3 + 5.2 grams

Blood pressure
Mean blood pressures during the equilibration period prior to
administration of a diuretic, during the baseline period immediately
following equilibration, and at the end of the study were compared
to respective controls.

Results are listed in Table 1.

As can be

seen, mean blood pressures in each group a did not differ
significantly from its respective control group b.
However, it should be noted that in group I la (HCTZ) and 11b
(HCTZ control) there was a significant fall in blood pressure in both
groups (-14.3 + 3.4 and -18.3 + 3.3 mm Hg, respectively) immediately
following administration of either the drug or its control.

This was

in contrast to all other groups where no such change in blood pressure
was observed, and was probably due to the vasodilatory effects of the
fairly large ethanol percentage required to dissolve the HCTZ.

However,

blood pressures in group I la did not differ significantly from its
control group 11b, and by the end of the study blood pressures in both
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groups had risen to levels comparable to the other groups.
Hematocrit
The mean hematocrit in each group a at the beginning of the
study was not significantly different from its respective control
group b.

Mean hematocrits at the end of the study and the increment

between initial and final hematocrits were also not significantly
different between experimental and control groups.
KC1 dose
The amount of KC1 infused was similar in all groups, and ranged
between 0.17 + 0.1 mEq/100 gm body weight/hour.
Potassium loading study
Mean plasma K and Na concentrations were similar in all groups
during the baseline period (see Table 2).

The results of the potassium

loading studies are shown in Table 2 and Figures 4-7.
The maximal increment in plasma K concentration after one hour
of KC1 infusion ( AT^) is listed for each group in Table 2, and was
similar in each group.

As can be seen graphically in Figures 4-7,

the rise in plasma K concentration during KC1 infusion in the groups
of rats given diuretics closely approximated the rise in plasma K
in their respective controls.

Differences in increments between

plasma K at given time intervals and plasma K during baseline periods
(AT.|- AT^) were not statistically significant.
Plasma Na concentration at baseline varied from 137.2 +_ 2.7 to
143.2 +1.30 mEq/L.

There were no significant changes in plasma Na

concentrations during study.
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Discussion

It has been a long standing assumption that diuretics have little
effect on electrolyte transport outside the kidney (122).

However, in

view of the fact that more needs to be known regarding their mechanisms
of action within the kidney and their effects of electrolyte homeostasis,
further study of their actions both within the kidney and in extrarenal
tissues is warranted.
The purpose of this study was to examine the effects of diuretics
of three different chemical families on extrarenal potassium disposal.
The results indicate that furosemide, bumetanide, hydrochlorothiazide,
and spironolactone at the doses employed do not significantly alter
the ability of the acutely nephrectomized rat to tolerate a potassium
load.

The increments in plasma K following intravenous KC1 administration

were not significantly different in animals given diuretics as compared
to controls given no diuretics.
While the present study shows no significant changes in potassium
disposal with the diuretics used, there is information in the medical
literature that made us suspect that these agents could have an
extrarenal effect on potassium homeostasis.

Hypokalemia is a common

complication of diuretic therapy in man (120) and is generally
attributed to potassium losses in the urine.

However, there have been

suggestions made in recent years that the etiology of the observed
hyperkalemia may not be as simple as an increase in potassium excretion,
and that changes in internal potassium balance may be among the
extrarenal effects which diuretics could possess.

Since the reasons
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for pursuing an extrarenal effect on potassium disposal differ with
each diuretic, the three families of diuretics used in this study will
be discussed separately here.

I. Furosemide and Bumetanide
Furosemide, like the other "high ceiling" diuretics including
bumetanide (Figure 1), inhibits sodium and chloride reabsorption in
the thick ascending loop of Henle (122,123).

Although the mechanism

of its action is not fully understood, it appears to involve primarily
inhibition of the active transport of Cl at the luminal membrane of
tubular cells in the ascending limb (122,123), resulting in increased
flow to the distal tubule and collecting system.

This causes an

impairment of urinary concentrating and diluting ability and increased
urinary Na, Cl, K, and water losses.

Like the rest of the high

ceiling diuretics, the diuretic potency of furosemide far exceeds
diuretics of other classes (124,125).

Bumetanide appears to have an

action similar to that of furosemide, and has a higher milligram
potency in dogs and in man (119,120).
A number of extrarenal effects of furosemide on systemic hemodynamics
have been described, including its action on pre-load reduction (1) and
its action as an antihypertensive agent (126-128).

As mentioned

earlier, furosemide has been shown to induce acutely an increase in
venous capacitance which precedes its natriuretic effect (1,129,130).
The observed decrease in left atrial and left ventricular filling
pressures is probably due to increased renal blood flow as well as to
increased peripheral venous capacitance (1,131).

As noted by Dikshit
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et a 1. (1), this furosemide-induced hemodynamic effect is more rapid
than the inotropic effect of digitalis, and may be more beneficial
in the setting of acute myocardial infarction not only due to its
effects on relieving pulmonary edema and congestion but also to its
relative lack of demand on myocardial oxygen requirements.
Furosemide has been used widely as an antihypertensive agent.
Immediate decreases in blood pressure are probably mediated by volume
changes.

However, the mechanism of its hypotensive effect in chronic

use is felt to be distinct from its diuretic activity.

This is

supported by the observation that furosemide in large doses has been
noted to be an effective antihypertensi ve in the presence of renal
insufficiency (1 32,1 33).

Although the effect of decreasing blood

pressure is not fully understood, it probably involves a number of
factors, including increased peripheral venous capacitance (1,134),
decreased peripheral arteriolar resistance (126,135), and increased
peripheral blood flow (126,1 35).
There has recently been described an electrolyte cotransport
system capable of producing net sodium, potassium, and chloride
movement intracel lularly (10,14,15,19,108-113).

The in vivo

physiologic significance of this mechanism is not known.

However,

it has been postulated that it acts in opposition to the Na-K ATPase
which extrudes Na from dells, and that it may have a significant
role in the regulation of cellular volume as well as in electrolyte
balance (11,12,112,113).

Moreover, it is of interest that the mechanism

has been demonstrated to exist in the loop of Henle (19) and is
inhibited by furosemide.

The cotransport is probably the mechanism
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of "active" chloride transport in the ascending limb.

This postulate

does not necessarily contradict evidence that chloride transport in
the thick ascending loop is dependent in some way on Na-K ATPase
activity (123).

As outlined by Aronson (118) and Crane (136), secondary

active transport is by definition not directly dependent on active
metabolic expenditure.

However, there must be an indirect linkage

to some such primary active process in order for it to continue.

For

example, many known secondary active transport systems involve coupling
of the transport of substances against their electrochemical potential
differences to the movement of sodium down its electrochemical gradient.
In order to maintain the sodium gradient oriented to allow sodium flux
into cells, an active transport mechanism to extrude sodium from cells
must exist.

Otherwise the gradient would dissipate and any transport

process coupled to sodium movement would cease.

For example. Crane

has proposed this form of couple transport as the mechanism of active
intestinal glucose absorption (136).

In the intestinal epithelium,

a primary active mechanism in the basolateral membrane actively pumps
Na out of cells at the expense of ATP, hence maintaining the Na
electrochemical gradient directed toward allowing Na movement into
cells.

In this manner, secondary active transport of such compounds

as glucose can continue across the luminal membrane.

Frizzell et al.

(137) have proposed a similar mechanism for active chloride transport.
A similar type of transport may be effective in the ascending loop
of Henle.

That is, the postulated Na-K-Cl cotransport mechanism

may be linked secondarily to a primary active Na-K ATPase pump.
Hence, inhibition of the pump, for example by ouabain, would indirectly
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but surely block Cl uptake in the ascending limb as has been
observed (123).
As mentioned, the physiologic significance of this cotransport
system is not known.

However, if the mechanism is an important

regulator of electrolyte balance not only in the loop of Henle as
has been suggested, but in the whole animal as well, then one would
expect that inhibition of the transport could have significant i n vi vo
consequences.

Of particular interest to this study are the possible

effects of cotransport inhibition on extrarenal potassium homeostasis.
The nephrectomized rat model used for the present study excludes
renal effects on electrolyte balance.

If blocking the cotransport

mechanism with furosemide or bumetanide causes inhibition of potassium
movement into cells, then one would expect to see a decrease in K
tolerance in response to an acute K load.

There is precedent to look

for these effects in the whole animal in that the cotransport system
is known to exist extrarenally in human red blood cells (14-18).
However, as is evident in Figures 4 and 5, this was not the case with
either furosemide or bumetanide.

The timed increments in serum

potassium observed in both furosemide-treated and bumetanide-treated
animals were not significantly different from the increments observed
in their controls.

These results argue against the postulate that

the cotransport mechanism is a major regulator of in vivo extrarenal
K homeostasis.
It is not surprising that bumetanide failed to cause any significant
change in K tolerance.

As pointed out by Palfrey et al. (10), the

ability of the aminobenzoic acid derivatives to inhibit the cotransport
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mechanism is directly related to diuretic potency.

Bumetanide is

not effective as a diuretic in the rat (120), and the results obtained
here support their conclusion.

However, furosemide is known to be an

effective and potent diuretic in the rat, and it was expected that it
might cause a change in K tolerance.
It should be noted that the cotransport mechanism has never been
studied in the whole animal.

It is certainly possible that it does

function as an important regulator of extrarenal electrolyte
homeostasis, but that its effects on electrolyte balance are not
detectable by the techniques used here.

As outlined previously, the

mechanism has been studied in isolated cell systems in which other
factors known to influence K homeostasis in vivo can be controlled.
The physiologic constraints of using a whole animal model can
be numerous.
Keeping this in mind, the fact that no effect on K tolerance was
seen does not necessarily imply that the cotransport system is not
operative.

It may be that other regulators of K homeostasis are either

more important in vivo or dominate K regulation in this particular
setting.

For example, the stress of anesthesia and surgery in these

animals has been documented to result in persistently elevated
epinephrine levels (30).

-adrenergic agents are known to stimulate

cotransport in isolated cell systems; their effects oppose those of
such agents as furosemide.

Therefore, in the experimental set-up used

here, one would expect the cotransport mechanism to be maximally
stimulated by epinephrine prior to administration of furosemide.

The

results obtained showing no change in K tolerance in furosemide-treated
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animals when compared with controls may be explained by this maximal
^-adrenergic stimulation.

This may indicate either that ^5-adrenergic

stimulation is the dominant regulator of the cotransport mechanism
or that ^-adrenergic stimulation is not reversible at the doses of
furosemide used.

This raises another issue.

The transport mechanism

is known to be inhibited by concentrations of furosemide in the range
of 10

-5

- 10

-3

M (10).

Furosemide, like other organic acids, is

actively secreted into the proximal tubule (138) and concentrated in
the tubular lumen, and is known to inhibit chloride reabsorption at
concentrations of 10

-6

- 10

-5

M in the lumen of the ascending limb (122).

The volume of distribution of furosemide is 10% body weight, and in
plasma, the drug is 95% protein bound (139).

At the dose used in these

experiments (20 mg/kg), one would estimate that the concentration of
_5
free circulating drug would be approximately 3 X 10

M.

This is near

the lower limit of concentrations at which an effect is seen on
cotransport in isolated cell systems, and it is possible that the free
fraction of drug in this experimental setting may not have been
sufficient to effect cotransport inhibition.

It would be of interest

to accurately determine if concentrations obtained with the dose used
are within the range known to produce inhibition in vitro; however,
this was beyond the scope of the present experiments.
The role of cotransport on electrolyte homeostasis merits further
work.

It would be interesting to repeat these experiments in a setting

in which factors which might interact or interfere with its effects
could be better controlled.

In particular, its significance in tissues

known to participate in K storage and regulation, such as muscle or liver.
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should be pursued.

There are also a number of ways in which the

design of these experiments could be modified and possibly improved.
For example, pH, bicarbonate levels, and hormone levels were not
measured in the present study.

Had there been significant changes

in K tolerance noted, these would have been explored more thoroughly.
Also, it is possible that following another electrolyte besides K
would be informative.
IK : INa : 2C1.

The postulated stoichiometry of the system is

It may be that the changes brought about in K

balance were too small to be quantitated in the face of the large
K load administered.

Under these circumstances, measuring chloride

concentrations might have yielded more significant results, since
twice as much Cl is transported as K.

If K infusion could be used

in the same manner to stress the cotransport system, but with an
anion other than Cl, then monitoring response to the inhibition of
the cotransport mechanism by following chloride concentration might
be more fruitful.

II. Hydrochlorothiazide
Thiazides are among the most commonly used diuretic agents.

The

mechanism of the action of thiazides within the kidney is not fully
understood, but appears to involve inhibition of reabsorption of
sodium and chloride in the distal tubule via an interaction with
specific renal receptors (120,140).
Numerous extrarenal effects of thiazides have been described.
Their use in the treatment of hypertension is perhaps the most obvious.
Initially thiazides cause a decrease in blood volume and a drop in
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cardiac output due to their diuretic activity.

However, during chronic

therapy, cardiac output returns to normal and peripheral resistance
falls (141,142), thereby maintaining a relatively hypotensive state
(3,4).

This effect is not related temporally or in magnitude to the

diuretic effect per se, and persists after normalization of the
cardiac output.
Other extrarenal effects of thiazides include an association of
their use with impaired glucose tolerance (144-147).

The mechanism of

this effect is not known but is felt perhaps to involve production of
hypokalemia which then limits insulin secretion (147,148).
also have major effects on metabolic balance.

Thiazides

Koppel et al.

(149)

have demonstrated an extrarenal effect of thiazides on calcium balance.
In patients with end stage renal disease and hypertension treated with
thiazides, a distinct hypercalcemic effect was noted.

These authors

postulate that this may have resulted from potentiation of the action
of parathyroid hormone in these patients who often have underlying
parathyroid gland hyperplasia secondary to their renal disease.

A

hypermagnesemic effect was also noted in these patients, which was
felt to be attributable to decreased renal Mg excretion and perhaps to
an increased release of Mg from bone or soft tissues.
Of most interest to the present study is the suggestion by
several investigators that thiazides have an extrarenal effect on
potassium homeostasis.

There is significant controversy over what

effect thiazides have on serum and total body potassium.

Some

investigators report significant reductions in total body potassium
with thiazide use (150-152) while others report no reduction in total
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body K (151,153-155).

Oh and Carroll (156) have pointed out that a

mathematically significant fall in total body K may not be physiologically
significant.

Nevertheless, the hazard of hypokalemia in patients

on thiazides is evident, particularly in the setting of myocardial
disease, hypertension, digitalis use, and liver cirrhosis in which they
are often used.
It is a common clinical observation that a significant number of
patients using thiazide diuretics have a fall in serum potassium (157).
Chronic hypokalemia is thought to result from increased aldosterone
secretion due to elevated renin levels secondary to chronic diureticinduced oligemia (158).
Gaul

This is supported by the work of Sweet and

(157) who noted that thiazide-induced hypokalemia could be corrected

by adding a ^,-adrenergic blocking agent, theoretically by decreasing
plasma renin activity.

However, these authors point out that the

diuretic produced a lowering of serum potassium even when plasma renin
was suppressed to pre-treatment levels by ^-blockade.

It is striking

that thiazide-induced hypokalemia is so commonly observed in view of
multiple demonstrations that total body potassium is unchanged even
with prolonged thiazide use.

Recently a number of groups have

postulated that the hypokalemia associated with thiazide administration
may reflect redistribution of potassium rather than an absolute reduction
of total body potassium (23,24,159).
In a study on the use of thiazides in hypertensive patients,
Talso and Carballo (159) noted that 85% of these patients demonstrated
a decrease in serum potassium concentration, yet simultaneous
determinations of total body potassium revealed no significant changes
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in the body content of the cation.

They postulated that alterations

in acid-base balance, notably the metabolic alkalosis often observed
with thiazide use, might have a significant effect on the production
of hypokalemia by causing redistribution of potassium.

However,

while alterations in extracellular pH and replacement of hydrogen ion
in the form of ammonium chloride did favorably alter serum potassium
status during thiazide administration, these authors noted that
supplementation of the extracellular hydrogen ion concentration was
not the sole mediator of the extracellular potassium concentration,
and suggested that other factors, including perhaps an effect of
thiazides on the permeability of the cell membrane to potassium, were
involved in determining the level of serum potassium.
There have been a number of cases described in the pediatric
population of hyperkalemia occurring in the setting of normal renal
and adrenal function and associated with acidosis and hypertension (21,
22).

Recently, the phenomenon of hyperkalemia following renal

transplantation but unrelated to graft rejection has been noted in a
significant percentage of post-transplant patients (23).
al.

DeFronzo et

(23) noted that this was present in 23 of 75 consecutive transplant

patients within three months of transplantation, and was present in
the absence of acidosis, renal

insufficiency, and rejection.

It was

also noted that the observed hyperkalemia was corrected by administration
of hydrochlorothiazide.

The authors have postulated that the transient

defect in tubular K secretion observed post-transplantation was due
either to decreased tubular basolateral membrane K uptake or to decreased
luminal membrane permeability to K, and that the effectiveness of
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thiazide in reversing the hyperkalemia may be due to alteration of
either or both of these cellular defects.

The authors also point out

the possibility that thiazides may have actions on extrarenal potassium
distribution which could account for or at least contribute to the
observed decrease in serum K.
In another recent study, Farfel et al.

(24) have described two

cases in which hypertension and hyperkalemia associated with normal
renal function, low plasma renin activity, and normal plasma
aldosterone levels were corrected with thiazide administration.

The

authors have postulated that the etiology of the observed syndrome
lies in a defect in cell membrane potassium transport.

Of particular

interest to the present study was the fact that thiazide administration
caused serum K to fall to normal values in the absence of a significant
increase in urinary K excretion in either patient.

In general it has

been assumed that the hypokalemic effect of diuretics is due to their
action of increasing renal K losses.

However, these results support

the theory that an extrarenal effect of thiazides causing cellular K
redistribution plays a significant role in their hypokalemic effect.
There is, then, precedent to believe that thiazides may have
extrarenal effects on potassium homeostasis.

The model used for the

present study was chosen for its exclusion of renal effects.

If the

hypokalemic effect of thiazides is caused by cellular redistribution of
potassium, one would expect that tolerance to a potassium load would
be improved in their presence.
Figure 6, this was not the case.

However, as is evident graphically in
The timed increments in serum

potassium observed in thiazide-treated animals were not different from
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the increments observed in their controls.

These data argue against

the postulated extrarenal hypokalemic effect of thiazides.

It is

unlikely that the dose of hydrochlorothiazide was insufficient
since this is a maximally natriuretic dose (143), and since it is
several times greater than the usual daily oral dose in human
subjects.

However, it is possible that an effect does exist, but

that its magnitude is not great enough to maintain a significant
lowering of plasma potassium in the face of the large KC1 infusion
used in these experiments.
III. Spironolactone
The introduction of the aldosterone-antagonist spironolactone in
1957 (160) represented one of the first cases in which knowledge of the
biochemical structure of a compound with known biologic effect was
used to search deliberately for and synthesize a specific pharmacologic
agent.

In view of the fact that aldosterone itself had not been

isolated until 1952 (161 ), this was a remarkable accomplishment.
Spironolactone is a competitive inhibitor of aldosterone.

It

does not inhibit secretion of aldosterone or of any of the other adrenal
steroids, but antagonizes the effect of aldosterone by combining with
specific target tissue receptor sites (162,163).

In the kidney it

antagonizes the aldosterone-stimulated K secretion and Na reabsorption
that occurs in the distal tubule (120).

In the absence of aldosterone,

spironolactone has no effect on renal electrolyte excretion (163), but
if aldosterone is present spironolactone promotes a natriuresis
regardless of the level of mineralocorticoid (164).

Potassium retention
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occurs only if there is a concomitant low sodium intake, and this
action can be overcome by sufficiently increased levels of aldosterone
(165,166).

Use of spironolactone may induce hyperkalemia; however,

with chronic use serum K levels return toward pre-treatment levels
(1 67,168).
Spironolactone induces a modest hypotensive effect in most
hypertensive patients, and has a synergistic hypotensive effect with
other diuretics (169).

That this action is distinct from a purely

volume depleting effect due to its diuretic action is shown in that
expansion of the extracellular fluid volume with dextran, plasma, or
saline does not abolish its effect (170).
Evidence exists that mineralocorticoids increase extrarenal
tissue K uptake in the whole animal (25,27-29).

As this has been

discussed in the introduction, studies supporting this hypothesis will
not be reiterated here.

The availability of spironolactone as a

selective inhibitor of aldosterone activity can be used as a tool to
further investigate this theory.

Moreover, in view of the fact that

there is precedent in the example of insulin to believe that basal
levels of hormones may play a role in K regulation, it is of interest
to examine the effects of selective aldosterone blockade on extrarenal
potassium disposal.
If, as recently postulated, extrarenal potassium tolerance is
impaired in the setting of aldosterone deficiency (25,30), then one
would expect to see a decrease in the ability of animals given
spironolactone to tolerate a potassium load.

The results of the

present study indicate, however, that administration of spironolactone
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did not significantly alter the hyperkalemic response in nephrectomized
rats given an acute potassium load.

As can be seen in Figure 7, the

timed increments in plasma potassium observed in spironolactonetreated animals were not different from the increments observed in
control animals.

The conclusion to be drawn from these results is

that blockade of peripheral aldosterone activity does not impair the
ability of extrarenal tissues to dispose of potassium as has been
suggested.

This argues against the hypothesis that aldosterone plays

an important role in extrarenal potassium regulation.
The possiblity exists, of course, that the results obtained here
do not accurately reflect the effects of aldosterone inhibition.

It

has been noted clinically as well as experimentally that several days
of spironolactone administration are required to observe the effects
of aldosterone inhibition (169,171).

Although the doses used in

the present study should have been sufficient to induce aldosterone
inhibition, it is possible that a longer duration of administration
is necessary.

This was avoided in this study to prevent the effects

of spironolactone-induced increases in body potassium stores which
are observed with long term use of the drug.
Another possible explanation for failure to see decreased K
tolerance is the method used to administer the drug.

French and

Manery (172) have pointed out that intermittent administration of
depot preparations of aldosterone are not reliable in producing its
mineralocorticoid effect.

It would not be unreasonable to consider

that this might also be true of spironolactone, since the compounds
are chemically very similar.

One means of checking this would be to
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obtain plasma and tissue levels of the drug, but this was not
feasible here.
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Conclusion

The effects of furosemide, bumetanide, hydrochlorothiazide,
and spironolactone on extrarenal potassium homeostasis were studied
in acutely nephrectomized rats.

None of these agents altered the

ability of experimental animals to tolerate a potassium load.

We

conclude that, within the limits of the experimental design of this
study, diuretics do not modify extrarenal potassium disposal.

This

study provides no evidence that the changes in serum potassium
concentration observed with diuretic use are caused by any changes
other than alterations in renal potassium excretion.
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Table 1

Blood Pressure (mm Hg)

Increment in Blood Pressure
(mm Hg)

Equilibrium
Baseline
T^
mean (E)_mean (B)_

Group

(E) - (B)

T1 - (E)

Ia

100.0 + 5.3

1 04.0 + 3.9

107.0 + 3/1

4.0 + 4.2

3.0 + 3.0

lb

102.3 + 5.6

103.0 + 5.8

106.7 + 7.0

0.7 + 2.6

3.7 + 4.2

I Ia

106.0 + 7.2

87.0 + 8.8

94.7 + 5.7

-14.3 + 3.4

6.0 + 6.2

11 b

110.3 + 10.9

94.3 + 11.7

103.3 + 8.4

-18.3 + 3.3

9.0 + 3.8

Ilia

111.7 + 7.6

113.7 + 6.1

115.0 + 5.6

3.0 + 5.8

1.3 + 3.0

Illb

111.3 + 5.8

111.3 + 4.1

115.0 + 2.5

-0.3 + 2.2

2.0 + 3.5

IVa

112.0 + 6.1

111.3 + 9.4

108.7 + 10.7

-0.6 + 6.4

-2.7 + 2.7

IVb

110.7 + 11.6

100.7 + 11.0

103.3 + 8.8

-6.7 + 2.4

2.7 + 8.2

Table 1.

Blood pressure during equilibrium period (E), during
baseline period (B), and at the end of study (T»),
and increments in blood pressure between periods
(E) and (B) and between periods T, and (E).
All values are given as the mean + SEM.
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Table 2

Basel ine mean
plasma
Group

Increment in plasma

K

K

above baseline

(mEq/L)

(mEq/L)

&T-j

la

5.21 + .13

lb

^T^

AT2

aT3

.71 + .14

1.89 + .19

2.60 + .16

3.11 + .17

4.95 + .11

.96 + .18

1 .89 + .05

2.58 + .10

3.21 + .14

I la

4.57 + .15

.78 + .12

1.50 + .12

2.20 + .13

2.74 + .18

11 b

4.91 + .14

.67 + .17

1.50 + .17

2.10 + .17

2.69 + .26

Ilia

5.12 + .11

.88 + .07

2.15 + .06

2.85 + .07

3.32 + .12

111 b

4.83 + .19

.97 + .13

1.92 + .20

2.68 + .21

3.08 + 122

IVa

4.87 + .51

.61 + .16

1.59 + .18

2.55 + .16

3.31 + .25

IVb

4.66 + .44

1.02 + .03

1.81 + .08

2.94 + .15

3.67 + .20

Table 2.

Baseline mean plasma K concentrations.
Increments in plasma K concentrations above baseline at
timed intervals during KC1 infusion.
All values are given as the mean + $EM
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C,YY>"H
Hydrochlorothiazide

Spironolactone
fr\

NH-CH^CHgCHgO^

COOH

Bumetanide
Figure 1

Chemical structures of furosemide, hydrochlorothiazide,
spironolactone, and bumetanide.
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Minutes of KCI Infusion

Figure 4

Figure 4.

Increment in plasma K concentration above baseline in
control (#-• ) and furosemide-treated (o—o) animals.
KCI was infused from T = 0 to T = 60 minutes.
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Minutes of KCI Infusion

Figure 5
Figure 5.

Increment in plasma K concentration above baseline in
control (•—• ) and bumetanide-treated (o—o)
animals. KCI was infused from T = 0 to T = 60 minutes.
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Minutes of KCI Infusion

Figure 6

Figure 6.

Increment in plasma K concentration above baseline in
control ( «—• ) and hydrochlorothiazide-treated ( o—o )
animals. KCI was infused from T = 0 to T = 60 minutes.
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